CANCER: Treating the Cause – Not Managing Symptoms

Cancer is not random. It follows biological patterns. We identify them.

Most cancer care focuses on treating what can be seen: the tumor, the symptoms, the side effects. But the underlying drivers – the biochemical and toxicological forces that allowed cancer to develop in the first place – are rarely investigated. That gap creates relapse, chronic fatigue, and stalled recovery.

My work starts before treatment, beside treatment, and after treatment: I uncover what your cancer biology is responding to.

Why conventional testing misses the real drivers

Standard bloodwork rarely measures the factors that destabilize DNA repair, overload mitochondria, disrupt hormones, or weaken the immune system’s surveillance. This means many patients are treated, but not understood.

For cancer, the question is rarely “Which diet?”

It is almost always: “Which carcinogens are present – and why hasn’t your system cleared them?”

The overlooked causes that change everything

Research links multiple toxin classes to cancer risk and progression:

• Pesticides and environmental chemicals

• Xenoestrogens and synthetic hormone disruptors

• Heavy metals (mercury, cadmium, lead)

• Mycotoxins from mold exposure

• Chronic infections that alter immune signaling

You cannot “eat your way out” of a poisoning problem.

A heavy-metal burden does not disappear with kale.

Mold toxins do not resolve because you avoid sugar.

Food supports healing – but toxins determine whether healing is possible.

The BioIntel Method: How I identify what really drives your cancer biology

1. Assess

We start with a detailed exposure and symptom mapping to determine which carcinogenic patterns are likely at play.

2. Identify

Using advanced laboratory testing, we measure mycotoxins, heavy metals, inflammatory metabolites, mitochondrial damage markers, hormone disruptors, and detoxification capacity.

3. Remove

Targeted detoxification protocols based on lab data – not guesswork – supervised in collaboration with US physicians when needed.

4. Rebuild

We support mitochondrial repair, immune recalibration, and metabolic stability so the inner environment becomes inhospitable to cancer.

This structure is not alternative.

It is biochemistry applied correctly.

What we often find in cancer clients

Hidden mycotoxin exposure suppressing immunity and driving inflammation

Heavy-metal retention impairing DNA repair and detox pathways

Hormonal patterns (estrone dominance, cortisol collapse) tightly linked to breast, prostate, and colon cancer risks

These factors rarely appear in standard care, yet they profoundly influence treatment response and recurrence patterns.

Why timing matters

The earlier we intervene, the stronger the biological foundation becomes – whether you are in active treatment, between scans, or recovering after therapy. The goal is simple: reduce your internal cancer pressure and increase your body’s resilience.

It is essential to be open with relatives about your choices, so they can support your plan.

If you want targeted treatment instead of symptom chasing

We review your history, your exposures, and which tests matter for your specific case.

From there, I build a customized program using laboratory diagnostics and US doctor–supervised scans.

Your biology is telling you a story.

My job is to decode it

Christina Santini is a clinical nutritionist specializing in cancer biology, toxicology, and advanced laboratory diagnostics. She has more than 20 years of international experience from clinics in Los Angeles and New York, working with functional medicine, biological medicine, and test-based strategies for complex patients. Her focus is not symptom relief but biochemical risk profiling: identifying the toxic, hormonal, and metabolic drivers that create a cancer-promoting internal environment. She collaborates with U.S. physicians, utilizes highly specialized laboratories, and develops targeted programs that address root causes rather than symptoms.

Go to our results to read more about how we work.

References

Carcinogenesis. 2010 Jan; 31(1): 71–82.

Front Cell Infect Microbiol. 2018; 8: 60.

J Prev Med Public Health. 2014 Mar; 47(2): 74–83.